Liquid Biopsies


Liquid Biopsy Using Wavesense Device:

- Isolation of Target Cells from Peripheral Blood.
- Isolation of Target Cells from Bone Marrow.
- Isolation of Target Cells from Urine for Prostate and Bladder.
- FDA approved device





3030 Venture Lane, Suite 108 • Melbourne, Florida 32934 • Phone 321-253-5197 • Fax 321-253-5199



CELL ENRICHMENT TECHNOLOGY

Studies have reported up to 82% capture of prostatic cells in voided urine after digital rectal prostate massage. This allows for a non-invasive evaluation of patients with an increased PSA. may also prevent subsequent biopsy procedure, in those patients with previous malignant diagnosis that have not had radiation therapy.

Using EpiSep cell enrichment technology, SunCoast Pathology is able to isolate Prostatic Glandular Epithelial Cells from the specimen and concentrate them onto a slide for genomic Fluorescent in-situ Hybridization (FISH) testing. This is achieved by using a paramagnetic antibody to malignant prostate cells (EpCam 323/3a) which adheres to the malignant cells and allows them to be deposited on a slide using the EpiSep HS enrichment device. The untagged cells are then wicked away from the target area and the preparation is then ready for genomic FISH testing.

EpiSep is an FDA approved device for detecting, isolating, and helping characterize Circulating Tumor Cells.

Liquid Biopsy for Metastatic Cancer Cells

- Breast
- Lung adenocarcinoma
- Colorectal adenocarcinoma
- Prostate Cancer
- Use EpCam Antibody Clone 323/A3



Liquid Biopsy for Prostate Cancer

- Non-invasive, liquid alternative to biopsy that uses only urine collected after digital prostate massage.
- Comprehensive and actionable results
- Using FISH for detection of prostate cancer
- Reduces the need for unnecessary biopsies and overall cost to the health system
- Enhances the patient's prostate cancer risk assessment

This testing is recommended for:

- Any patient with increase in PSA and/or prostatitis, considered to need a prostate biopsy by his Urologist using current standard practice.
- Patients with no prior diagnosis of prostate cancer.
- Patients not receiving treatment influencing PSA level.
- Patients who have not received a prostate massage within 24 hours of sample collection.
- Patients who have not ejaculated within 24 hours of sample collection.